

RESEARCH PAPER

## Development of Sulfadiazine by Nano Method and Study Its Effect Against Multi-Drug Resistant Bacteria

Ali Jaffar Saleem <sup>1\*</sup>, Alaa Salim Hamzah <sup>2</sup>, and Mustafa Hammadi <sup>3</sup>

<sup>1</sup> Department of Biology, College of Education for Pure Science, University of Diyala, Iraq

<sup>2</sup> Department of Anesthesia Technique, Institute of Medical Technology, Baghdad, Middle Technical University, Baghdad, Iraq

<sup>3</sup> Department of Chemistry, College of Education for Pure Science, University of Diyala, Iraq

### ARTICLE INFO

#### Article History:

Received 03 July 2024

Accepted 21 September 2024

Published 01 October 2024

#### Keywords:

EDX

Nano-Antimicrobial

*Pseudomonas aeruginosa*

SEM

*Staphylococcus aureus*

### ABSTRACT

Nanotechnology-based antibiotic synthesis is one of the most crucial contemporary strategies for preventing antibiotic resistance. Synthesis of nano sulfadiazine antibiotic was nanoscale made by using standard sulfadiazine in this study, Physically, without using any chemicals. The resulting nanocomposite was examined using XRD, EDX, and SEM methods, and their characteristics were contrasted with those of nano sulfadiazine, whose average crystal size was 48.32 nm. The ability of nano sulfadiazine to prevent bacteria growth was examined MIC activity and it was compared to regular sulfadiazine particles. The results of the broth microdilution method with standard sulfadiazine gradient (concentration) ranges of 8-1024µg/ml show the MIC ranging 64-128µg/ml among five MDR *P. aeruginosa* isolates and five MDR *S. aureus* isolates. While the results of Nano-sulfadiazine MIC ranged from 16-32µg/ml for *P. aeruginosa*, isolates and 32µg/ml for *S. aureus* isolates.

### How to cite this article

Saleem A., Hamzah A., Hammadi M. Development of Sulfadiazine by Nano Method and Study Its Effect Against Multi-Drug Resistant Bacteria. J Nanostruct, 2024; 14(4):1023-1028. DOI: 10.22052/JNS.2024.04.003

### INTRODUCTION

One of today's biggest health system concerns is antibiotic resistance, which poses a significant health risk to the general public. Multi-Drug Resistance (MDR) is a problem that affects health care negatively on a global scale. Randomly use of antibacterial take place in distribution resistant bacteria because increase ability of resistance different types of these antibacterial [1,2]. Pathogenic organisms resistant to numerous chemotherapeutic treatments are said to exhibit multi-drug resistance [3]. The development of

MDR, which increases mortality and morbidity rates, is an extremely common occurrence among microorganisms. This procedure is becoming more prevalent for several reasons. The usage of unidentified antimicrobial agents is the most significant one [2]. Among the most common causes of severe nosocomial infections are *Pseudomonas aeruginosa* and *Staphylococcus aureus*. There are different types of bacteria (Gram negative and Gram positive) became multidrug resistance and extensive drug resistance [4,5,6].

*P. aeruginosa*, a common Gram-negative rod

\* Corresponding Author Email: [alijaffar3@yahoo.com](mailto:alijaffar3@yahoo.com)



found in nature, can infect immunosuppressed and critically ill people, leading to different clinical diseases. Gram-positive *S. aureus* is a common pathogen that primarily affects the skin and soft tissues in the general population, but it can also cause serious infections like pneumonia, respiratory tract infections, sepsis, infections at surgical sites, infections in prosthetic joints, and infections of the heart and blood vessels in hospitals [7].

The antibacterial capacity of silver and Ag+ increase of unstable form of electron's lead to occur structural damage in cell wall of bacterial cell and die of cell [8–10]. The efficiency of Ag+ as an antibacterial agent is strongly influenced by interactions with DNA, according to the available data. The Ag+ is commonly provided externally as a therapeutic. The substances silver (silver sulfadiazine) may be use in treatment skin infection [11–13]. The substances use in treatment different types of bacterial and parasite infection and limit distribution of infection because high activity and easy penetration of bacterial cell membrane [14–16]. These compounds may be use in different methos to reduce bacterial infection [17]. New methods for treating bacterial infections, creating alternative antimicrobial medications, reducing biofilm development, medication delivery, and cell therapy are anticipated to result from recent advances in nanotechnology [18]. Numerous benefits may be associated with nanoparticles. The majority of today's antibacterial substances are natural compounds that have been chemically changed [19].

**MATERIALS AND METHODS**

*Bacterial Identification and Antibiotic Susceptibility*

Patients resting in the Baquba Teaching Hospital in Iraq with burns and wounds were used to collect clinical samples. All samples were identified by routine work and certainly identification with antibiogram by VITEK® 2 Compact. The device

has unique data that converts the outcome of bacterial metabolism into numbers and provides a quick response in just eight hours.

*Converting sulfadiazine antibiotic to nanoscale*

Dissolved amount (0.2 Sulfadiazine 99.9%) in amount of water (100 mL of deionized water) and place it in an ultrasonic cleaner for half an hour at room temperature; it is shown in the reaction Fig. 1.

*Bacterial culture*

Bacterial samples were cultured in enrichment media (BHIB) and incubated (37 °C 24 hours). Then measured density of growth with standard McFarland 0.5 (1.5 × 10<sup>8</sup> CFU/ml). The optical density (OD 600) between 0.08 and 0.1 to ensure suitable amount of tested bacterial cells.

*Test MIC*

Different concentration (8-16-32-64-128-256-512-1024µg/ml) were done from stock of test substances (Sulfadiazine NPs). Then used microplates (contain 96 wells) with stock of antibacterial (Mueller-Hinton broth and bacterial suspension) with multiple replication, positive & negative control to ensure precise test. Technique ELIZA 630nm used in second day of end incubation period [20,21].

**RESULTS AND DISCUSSION**

*Nano Sulfadiazine Characterization by (FTIR)*

The results shown in Fig. 2 were compared with the standard sulfadiazine obtained from the Samarra Pharmaceutical Laboratory. It was confirmed that the peaks are identical and that conversion to nanoscale will not lead to any change. Where a band appeared at a frequency (3371, 3340 cm<sup>-1</sup>) belonging to the primary amino group (NH<sub>2</sub>), a band at a frequency (3255 cm<sup>-1</sup>) belonging to the secondary amine group (NH), a band at a frequency (3062.cm<sup>-1</sup>). ) returns (C-H )




Fig. 1. Reaction diagram (1) converting sulfadiazine antibody to nanoscale

of the aromatic ring, another band at frequency (1126, 1419  $\text{cm}^{-1}$ ) group ( $\text{SO}_2$ ), and a band at a frequency (1643  $\text{cm}^{-1}$ ) due to the expansion (C = C) of the aromatic ring, and a band at a frequency (1573.91  $\text{cm}^{-1}$ ) returns to (C = N), and the band at a frequency (1234  $\text{cm}^{-1}$ ) returns to (C-N) This agrees with the scientific literature[22].

*Characterization of Nano- Sulfadiazine by X-ray diffraction*

The X-ray spectra of Nano Sulfadiazine are in Fig. 3. The average size of the crystals by using the Debye-Scherrer equation was 48.32nm.

*Characterization by energy-dispersive X-rays*

EDS analytical technique was done to explain fraction of elements in Sulfadiazine (Fig. 4). According to this figure Silver 41.4% and

carbon 32.5%, nitrogen 6.9 %, and oxygen 5.1% Sulfadiazine NPs showed high purity .

*Characterization by scanning electron microscope*

Used (SEM scanning electron microscope) to detect precise structure details of this nanoparticles. The details in Fig. 5 refer to preparation of sulfadiazine in the nanometer. Scanning electron microscope results refer to composition of nanoparticles separated from each other. Also, most of them it found in a lumpy form. This agglomeration due to electrostatic effects and the average diameter of these particles is 63.54 nm.

*Measurement of the particle size of Nano sulfadiazine in liquid*

A particle size meter was used to determine the




Fig. 2. Infrared spectrum of a compound Nano- Sulfadiazine




Fig. 3. shows the X-ray diffraction spectrum of an antibody Nano Sulfadiazine

size of the sulfadiazine. The size of the standard sulfadiazine was compared. Fig. (6-A) shows its size equal to 2827.8 nm, and after conducting treatments on it, it was converted into a nano-antibody, where its size became 599.6 nm, as shown in Fig. (6-B).

**Antibacterial susceptibility test**

The results of antibiogram of the tested pathogenic bacteria (*P.aeruginosa* , *S.aureus*) isolated from skin infection (burn infection) showed that *P. aeruginosa* exhibited high resistance to different types of antibiotics

(Cefotaxime, Amikacin, Gentamicin, Ticarcillin-Clavulanate, Piperacillin, Cefepime, Ciprofloxacin, Tobramycin, Ceftazidime, Levofloxacin, Polymyxin, and Meropenem). Other pathogenic bacteria *S.aureus* was resistant to the antibiotics (Oxacillin, Levofloxacin, Vancomycin, Benzyl penicillin, Gentamicin, Tobramycin, Linezolid, Teicoplanin, Tetracycline, Tigecycline).

**Detection activity of MIC**

It is concentration that inhibit bacterial growth [23]. Table 1 and Fig. 7 showed results of MIC which some isolates 40% of *P. aeruginosa* with MIC




Fig. 4. Energy-dispersive X-ray spectrum of Nano Sulfadiazine




Fig. 5. SEM Nano Sulfadiazine SEM image.




Fig. 6. the granular size in the liquid of sulfadiazine.




Fig. 7. MIC test using microplates

Table 1. Minimum Inhibitory Concentration of sulfadiazine and sulfadiazine NPs

compounds	<i>Pseudomonas aeruginosa</i> MIC µg/ml				<i>Staphylococcus aureus</i> MIC µg /ml						
sulfadiazine	64	128	64	64	128	64	64	64	64	64	128
sulfadiazine NPs	32	32	16	16	16	32	32	32	32	32	32

128 µg/ml but other 60% with MIC 64 µg/ml. The nano-sulfadiazine MIC results of these bacteria 40% (MIC 32 µg/ml) and other isolates 60% (MIC 16 µg/ml). The standard sulfadiazine results showed that some *S. aureus* 20% (MIC 128 µg/ml) but other isolates 80% (MIC 64 µg/ml).

The increase in the effectiveness of Nano-sulfadiazine against *P. aeruginosa* and *S. aureus* compared to the standard sulfadiazine indicate that these nanoparticle with high antibacterial activity. These activity increase with penetration large amount from nanoparticle through membrane and reduce role of efflux pump mechanisms. Also,

these particles may be considered antibacterial agent to other types of multidrug resistance pathogenic bacteria and it use alone or mixed with different types of antibiotics in different relationship like synergism effect.

### CONCLUSION

Nano-sulfadiazine is few toxic and useful as antibacterial substance especially *Pseudomonas aeruginosa* and *Staphylococcus aureus* comparison with standard sulfadiazine. This substance can pass through bacterial cell membrane. Then this process led to increase

level of antibacterial substance. So, bacterial cell cannot use mechanisms of resistance because it lost activity of efflux pump system and other mechanisms. In future may be use this substance in treatment infection that cause with these bacteria and decrease using of antibiotics

#### CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this manuscript.

#### REFERENCES

1. Tanwar J, Das S, Fatima Z, Hameed S. Multidrug Resistance: An Emerging Crisis. *Interdiscip Perspect Infect Dis*. 2014;2014:1-7.
2. Vivas R, Barbosa AAT, Dolabela SS, Jain S. Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview. *Microb Drug Resist*. 2019;25(6):890-908.
3. Nikaido H. Multidrug Resistance in Bacteria. *Annual Review of Biochemistry*. 2009;78(1):119-146.
4. Sabat AJ, Pantano D, Akkerboom V, Bathoorn E, Friedrich AW. Pseudomonas aeruginosa and Staphylococcus aureus virulence factors as biomarkers of infection. *Biol Chem*. 2021;402(12):1565-1573.
5. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther*. 2013;11(3):297-308.
6. Savoldi A, Carrara E, Tacconelli E. Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list—authors' response. *J Antimicrob Chemother*. 2020;75(7):2018-2018.
7. Uhlemann A-C, Otto M, Lowy FD, DeLeo FR. Evolution of community- and healthcare-associated methicillin-resistant Staphylococcus aureus. *Infection, Genetics and Evolution*. 2014;21:563-574.
8. Russell AD, Hugo WB. *Antimicrobial Activity and Action of Silver*. Progress in Medicinal Chemistry: Elsevier; 1994. p. 351-370.
9. Dibrov P, Dzioba J, Gosink KK, Häse CC. Chemiosmotic Mechanism of Antimicrobial Activity of Ag<sup>+</sup> in Vibrio cholerae. *Antimicrobial Agents and Chemotherapy*. 2002;46(8):2668-2670.
10. Holt KB, Bard AJ. Interaction of Silver(I) Ions with the Respiratory Chain of Escherichia coli: An Electrochemical and Scanning Electrochemical Microscopy Study of the Antimicrobial Mechanism of Micromolar Ag<sup>+</sup>. *Biochemistry*. 2005;44(39):13214-13223.
11. Silver S, Phung LT, Silver G. Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds. *Journal of Industrial Microbiology & Biotechnology*. 2006;33(7):627-634.
12. Carr HS, Wlodkowski TJ, Rosenkranz HS. Silver Sulfadiazine: In Vitro Antibacterial Activity. *Antimicrobial Agents and Chemotherapy*. 1973;4(5):585-587.
13. Wlodkowski T, Rosenkranz H. Antifungal activity of silver sulphadiazine. *The Lancet*. 1973;302(7831):739-740.
14. Shifa B, Tofa B, Naziza R, Ruhul AK. A review on antibiotic resistance and way of combating antimicrobial resistance. *GSC Biological and Pharmaceutical Sciences*. 2021;14(2):087-097.
15. Roth L, Adler M, Jain T, Bempong D. Monographs for medicines on WHO's Model List of Essential Medicines. *Bulletin of the World Health Organization*. 2018;96(6):378-385.
16. Jijie R, Barras A, Teodorescu F, Boukherroub R, Szunerits S. Advancements on the molecular design of nanoantibiotics: current level of development and future challenges. *Molecular Systems Design and Engineering*. 2017;2(4):349-369.
17. Long NV, Yang Y, Teranishi T, Thi CM, Cao Y, Nogami M. Synthesis and magnetism of hierarchical iron oxide particles. *Materials & Design*. 2015;86:797-808.
18. Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. *Nature Materials*. 2014;13(2):125-138.
19. Sarkar A, Sil PC. Iron oxide nanoparticles mediated cytotoxicity via PI3K/AKT pathway: Role of quercetin. *Food and Chemical Toxicology*. 2014;71:106-115.
20. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. *BSI British Standards*.
21. An Overview of the Clinical and Laboratory Standards Institute (CLSI) and Its Impact on Antimicrobial Susceptibility Tests. *Antimicrobial Susceptibility Testing Protocols: CRC Press*; 2007. p. 15-20.
22. Liu X, Gan H, Hu C, Sun W, Zhu X, Meng Z, et al. Silver sulfadiazine nanosuspension-loaded thermosensitive hydrogel as a topical antibacterial agent. *International Journal of Nanomedicine*. 2018;Volume 14:289-300.
23. Methods for the determination of susceptibility of bacteria to antimicrobial agents. *Terminology. Clinical Microbiology and Infection*. 1998;4(5):291-296.